Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MGI Pharma Hexalen

  • News

Executive Summary

MGI Pharma will begin promoting second-line ovarian cancer chemotherapy Hexalen (altretamine) by early May using a 42-person sales force following its purchase of the product from MedImmune. Hexalen has had annual sales of $1.8 mil.-$2 mil. for the past few years, MGI Pharma indicated, and has not been actively promoted since late 1998. MGI Pharma will pay MedImmune $7.2 mil. plus royalties for 10 years. MGI Pharma may seek a supplemental indication for increased 2-year survival rate in women who received the drug during remission

You may also be interested in...



MGI Aloxi Launch Set For September; Indications Include Delayed Nausea

MGI Pharma plans to differentiate the antiemetic Aloxi (palonosetron) from other 5HT3 antagonists by highlighting a unique indication for delayed nausea in chemotherapy patients

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS036925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By